v3.26.1
CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES
3 Months Ended
Mar. 31, 2026
CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES  
CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES

3.            CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES

The following table summarizes the Company’s cash, cash equivalents and marketable securities as of March 31, 2026 and December 31, 2025, respectively:

March 31, 2026

  ​ ​ ​

Amortized Cost

  ​ ​ ​

Unrealized Gains

  ​ ​ ​

Unrealized Losses

  ​ ​ ​

Fair Value

Cash and money market funds

$

63,516,924

$

$

$

63,516,924

U.S. treasuries

62,416,903

(49,988)

62,366,915

U.S. government agencies

43,104,514

(45,063)

43,059,451

Corporate bonds

40,311,933

(105,950)

40,205,983

Commercial papers

69,513,367

(52,726)

69,460,641

Total cash, cash equivalents and marketable securities

$

278,863,641

$

$

(253,727)

$

278,609,914

Classified as:

Cash and cash equivalents

$

105,421,484

Short-term marketable securities

173,188,430

Long-term marketable securities

Total cash, cash equivalents and marketable securities

$

278,609,914

December 31, 2025

  ​ ​ ​

Amortized Cost

  ​ ​ ​

Unrealized Gains

  ​ ​ ​

Unrealized Losses

  ​ ​ ​

Fair Value

Cash and money market funds

$

287,847,312

$

$

$

287,847,312

U.S. treasuries

29,998,449

283,154

30,281,603

Total cash, cash equivalents and marketable securities

$

317,845,761

$

283,154

$

$

318,128,915

Classified as:

Cash and cash equivalents

$

287,847,312

Short-term investments

30,281,603

Long-term investments

Total cash, cash equivalents and marketable securities

$

318,128,915

The contractual maturities of the Company's available-for-sale securities at March 31, 2026 were up to approximately two years.

The Company does not intend to sell these investments for the purpose of realizing losses; however, the securities are classified as available-for-sale and may be sold in response to changes in market interest rates, liquidity needs, or other factors. The Company believes it is more likely than not that it will not be required to sell the investments before recovery of their amortized cost basis. Accordingly, the Company has determined that the available-for-sale securities that were in an unrealized loss position did not have any credit loss impairment as of March 31, 2026.